Trial Profile
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms READY
- Sponsors Bristol-Myers Squibb
- 01 Aug 2017 Results evaluating cardiovascular ischaemic event rates in dasatinib treated patients using patient data from NCT00103701, NCT00101647, NCT00101816, NCT00101660, NCT00101595, NCT00103844, NCT00123474, NCT00123487, NCT00481247, NCT00529763, NCT01357655, NCT00744497 trials and and comparing it with external reference populations published in the Annals of Hematology
- 10 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2014 as per ClinicalTrials.gov record.
- 18 Jan 2014 Status changed from active, no longer recruiting to completed.